An observational study in Febrile Illness, sponsored by Centre National de Formation et de Recherche en Sante Rurale. Recruiting at 1 site in Guinea. Open to participants aged 2 Months and older. Per ClinicalTrials.gov, last updated 2023-11-08.
Sponsored by Centre National de Formation et de Recherche en Sante Rurale · Observational
To date, the underlying causes of community-acquired fever, particularly non-malarial fever, are insufficiently documented in Guinea. Moreover, diagnostic capacity is limited, leading to inadequate prescription of antibiotics and antimalarials, as well as substantial delay in outbreak recognition. Thus, the investigators undertook a prospective observational multi-centric cohort study of febrile patients presenting at the emergency and outpatient department of selected health centers, districts and regional hospitals in four ecologically distinct sentinel health districts in Guinea.
Centre National de Formation et de Recherche en Sante Rurale is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Febrile patients presenting with documented fever (> 37.5°C, axillary temperature) or reporting fever within the prior 24 hours (≤37.5°C, axillary temperature) at the emergency or outpatient department of the selected health facilities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pattern of symptoms and laboratory results at presentation and during follow-up
Proportion will be estimated
Time frame: Day 0 and day 21
Syndromic and/or etiologic diagnoses as established at day 21
Proportion will be estimated
Time frame: Day 0
Pattern and duration of antibiotic use (and other treatments)
Proportion and mean or median will be estimated
Time frame: Day 0
Immediate or secondary hospital admissions and of secondary/unscheduled visits
Proportion will be estimated
Time frame: Day 0 and day 21
Participants alive (with or without symptoms) or dead at day 21.
Survival or mortality rate will be estimated
Time frame: Day 21
White blood cells and C-reactive protein levels at baseline and association with syndromic/etiologic diagnoses and with patient outcome at day 21
Mean or median level will be estimated
Time frame: Day 0
Association of seasonal, geographical, demographic, clinical and first-line laboratory variables (malaria RDT and smear, biochemistry) with presenting syndromes/main etiologies
OR or RR will be estimated as appropriate
Time frame: Day 0
Confirmed arboviral pathogens and identification of epidemiological/clinical/laboratory predictors
Proportions will be estimated
Time frame: Day 0
Cases fulfilling any of the case definitions of the 20 epidemic-prone infections under surveillance as compared to the final diagnosis and proportion of them timely reported to health authorities
Proportions will be estimated
Time frame: Day 0
Plan to share: Yes — This is under development and will be filled when finalized.
Supporting information: Study protocol
Time frame: Yet to be finalized.
Access criteria: Yet to be finalized. However, investigators are opened to collaborate on that data that will be generated.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre National de Formation et de Recherche en Sante Rurale